S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:DRMA

Dermata Therapeutics (DRMA) Stock Price, News & Analysis

$0.40
+0.01 (+2.55%)
(As of 03/28/2024 ET)
Today's Range
$0.40
$0.42
50-Day Range
$0.38
$0.52
52-Week Range
$0.37
$3.93
Volume
37,045 shs
Average Volume
90,419 shs
Market Capitalization
$1.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DRMA stock logo

About Dermata Therapeutics Stock (NASDAQ:DRMA)

Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

DRMA Stock Price History

DRMA Stock News Headlines

Dermata Therapeutics, Inc. (DRMAW)
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Dermata Therapeutics Inc DRMA
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Why Is Dermata Therapeutics (DRMA) Stock Up 62% Today?
Dermata Therapeutics Inc.
Dermata Therapeutics GAAP EPS of -$0.54
See More Headlines
Receive DRMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRMA
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-7,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.80 per share

Miscellaneous

Free Float
3,206,000
Market Cap
$1.42 million
Optionable
Not Optionable
Beta
0.87
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Gerald T. Proehl (Age 65)
    Founder, President, CEO & Chairman
    Comp: $352.92k
  • Mr. David F. Hale (Age 75)
    Co-Founder & Lead Independent Director
    Comp: $18.12k
  • Ms. Kyri K. Van Hoose CPA (Age 45)
    M.B.A., Senior VP & CFO
    Comp: $328.75k
  • Dr. Christopher J. Nardo M.P.H. (Age 59)
    Ph.D., Senior VP & Chief Development Officer
    Comp: $329.92k
  • Mr. Sean Proehl
    Senior Director of Legal & Business Development
  • Dr. Maria Bedoya Toro Munera M.B.A. (Age 72)
    Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance
    Comp: $27.04k

DRMA Stock Analysis - Frequently Asked Questions

How have DRMA shares performed in 2024?

Dermata Therapeutics' stock was trading at $0.61 at the beginning of 2024. Since then, DRMA stock has decreased by 34.1% and is now trading at $0.4020.
View the best growth stocks for 2024 here
.

When is Dermata Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our DRMA earnings forecast
.

When did Dermata Therapeutics' stock split?

Dermata Therapeutics shares reverse split before market open on Tuesday, March 14th 2023. The 1-16 reverse split was announced on Tuesday, March 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did Dermata Therapeutics IPO?

Dermata Therapeutics (DRMA) raised $18 million in an initial public offering on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share.

Who are Dermata Therapeutics' major shareholders?

Dermata Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (6.16%).

How do I buy shares of Dermata Therapeutics?

Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRMA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners